loading...| Preferred Name |
Quazepam |
|
| Synonyms |
|
|
| Definitions |
A synthetic benzodiazepine derivative with anxiolytic, sedative and hypnotic properties. Quazepam and its major metabolite 2-oxoquazepam potentiate gamma-aminobutyric acid (GABA) activity by binding to the benzodiazepine-1 recognition site (BZ-1) within the GABA-A receptor, located in the limbic, neocortical and mesencephalic reticular system. This increases the frequency of GABA-activated chloride channel opening events, allowing the flow of chloride ions into the neuron leading to membrane hyperpolarization and decreased neuronal excitability. |
|
| ID |
http://purl.obolibrary.org/obo/NCIT_C47699 |
|
| CAS_Registry |
36735-22-5 |
|
| Chemical_Formula |
C17H11ClF4N2S |
|
| code |
C47699 |
|
| Contributing_Source |
FDA |
|
| definition |
A synthetic benzodiazepine derivative with anxiolytic, sedative and hypnotic properties. Quazepam and its major metabolite 2-oxoquazepam potentiate gamma-aminobutyric acid (GABA) activity by binding to the benzodiazepine-1 recognition site (BZ-1) within the GABA-A receptor, located in the limbic, neocortical and mesencephalic reticular system. This increases the frequency of GABA-activated chloride channel opening events, allowing the flow of chloride ions into the neuron leading to membrane hyperpolarization and decreased neuronal excitability. |
|
| FDA_UNII_Code |
JF8V0828ZI |
|
| in_subset | ||
| label |
Quazepam |
|
| Legacy Concept Name |
Quazepam |
|
| NSC Number |
309702 |
|
| Preferred_Name |
Quazepam |
|
| prefixIRI |
NCIT:C47699 |
|
| prefLabel |
Quazepam |
|
| Semantic_Type |
Pharmacologic Substance |
|
| UMLS_CUI |
C0072828 |
|
| subClassOf |